Suzhou, China, October 13, 2023 – TenNor Therapeutics announced that its investigational new drug rifasutenizole (TNP-2198) for the treatment of H. pylori infection had been granted Fast Track designation by the FDA.

Rifasutenizole is a multi-targeting drug conjugate discovered and developed by TenNor Therapeutics. It has potential to become the first novel antibacterial drug specifically developed for H. pylori infection. TenNor has completed five clinical trials in China and is currently conducting a multi-center, randomized, double-blind, bismuth-containing quadruple therapy-controlled phase III clinical trial in support of NDA in China and the US. TenNor Therapeutics owns the global intellectual property rights for rifasutenizole. TenNor has previously received QIDP designation for rifasutenizole from the FDA. This product is also supported by the National Major New Drug Innovation Grant in China.

About TenNor Therapeutics

TenNor Therapeutics is a clinical-stage company specialized in the discovery and development of differentiated new drug products in diseases associated with bacterial infection and metabolism. TenNor possesses a unique multi-targeting drug conjugate technology platform and a strong new drug development pipeline with global IP protection. Several products are currently in late-stage of clinical development targeting H. pylori infection, implanted medical device infections, hepatic encephalopathy and irritable bowel syndrome with diarrhea. The company is committed to address the unmet needs in the disease area and provide safe and effective therapies for patients in China and around the world.

For more information, please visit: www.tennorx.com